Seventy percent of the mice receiving (S,S)-1,2-bis(5-methoxy-2-benzimidazolyl)-1,2-ethandiol (A36683) in their drinking water lived at least four times longer than control mice when infected with 10 or 100 mean lethal doses of lymphocytic choriomeningitis virus strain UBC. In the next 4 months, most of the survivors died with lymphocytic choriomeningitis-like symptoms. Drug treatment during the first 7 days after infection was found to have no significant effect on virus titers in various organs. The sparing effect of the drug is discussed in terms of immunosuppression.
In the previous paper (6), we established that the dihydrochloride salt (A37536) of (S,S)-1,2-bis(5-methoxy-2-benzimidazolyl)-1,2-ethandiol was a potent inhibitor of arenavirus synthesis in a mouse origin continuous tissue culture line (L cells). The object of the present study was to determine the in vivo efficacy of the parent compound (A36683) and its salt (A37536) by using lymphocytic choriomeningitis (LCM) virus-infected mice as a model system.
MATERIALS AND METHODS
Virus and assay techniques. LCM virus strains UBC, WCP, and CA1371 (4) were titrated by a plaque method using the BHK-21/13S agarose suspension system employed previously (6), or by a conventional mean lethal dose (LDI.) assay (7) using intracerebral inoculation of five 12-to 14-g white ICR female mice (Blue Spruce Farms, Altamont, N.Y.) with 0.03-ml volumes of serial 10-fold dilutions of virus. Virus content of organs was determined as follows. Mice were killed by cervical dislocation, with immediate aseptic removal of the brain, liver, kidneys, lungs, spleen, and heart. Organs were ground with sand in a mortar and pestle, followed by suspension in tissue culture medium (1 ml/organ). This was centrifuged at 1,000 rpm for 5 min, and the virus content of the supernatant was titrated by plaque assay.
Chemotherapy tests. All compounds referred to in this paper by their "Abbott number" are those listed in Table 1 of the previous paper (6) . The water-soluble hydrochloride salts were suspended in distilled water. The remaining compounds were suspended in distilled water, shaken for 12 h, and then mixed with an equal volume of 2% Methocel (Dow Chemical Co., Midland, Mich.). In this way, fairly uniform suspensions could be maintained with shaking for 30 s every 12 h. All stock solutions (usually 1 mg of the compound per ml) were stored at 4 C for no longer than 5 days before use. Continual drug treatment, starting at 
RESULTS
Treatment conditions. Groups of six 12-to 14-g mice were given various concentrations of A37536 and A36683 in the drinking water. These groups were weighed daily for 7 days, along with controls, to determine the weight gains. Water intake was measured by weighing the drinking bottles daily. Optimal drug intake in both cases was found to be 1 mg of compound per ml of drinking water. This concentration of A36638 allowed normal weight gain and water intake at a dosage level of 330 mg/kg per day. On the other hand, this concentration of A37536 led to less than half the normal water intake and slightly retarded weight gain with a dosage level of 150 mg/kg per day.
Initial curative trials. Groups of 10 to 20 mice were infected with 1, 10, and 100 LD,0 of LCM virus strain UBC. Significant protection was noted with mice receiving A36638 and 10 or 100 LD,0 of virus. A typical survival curve is shown in Fig. 1 All mice exhibited the typical LCM virusinduced postmortem convulsion position (rear legs extended, forelimbs flexed, neck extended, and thoracic spine flexed). At termination of the observation period, 20% of the originally infected mice survived, whereas 70% had survived the first 30 days. Blood samples taken at this time showed 60% of the mice to be free of detectable virus, whereas the remainder had titers ranging from 103 to 5 x 104 plaque-forming units per ml.
A36683 influence on virus synthesis. Forty 12-to 14-g mice were injected with 10 LD,0 of LCM-UBC; 20 of these were treated with A36683 in the above manner. Every day for 7 days, two mice from each group were sacrificed and their brains, livers, kidneys, lungs, and spleens were removed. The virus content of each organ was individually determined from mice taken on days 3, 5, and 7 after infection. No significant difference could be seen in the virus content of organs taken from either drugtreated or control mice. The death rate of the unsacrificed mice followed the pattern established in Fig. 1 . DISCUSSION Data in the previous paper (6) indicated that the hydrochloride salt of (S,S)-1,2-bis(5-methoxy-2-benzimidazolyl)-1,2-ethandiol (A37536) was a potent inhibitor of LCM virus in L cells of mouse origin. Evidence has been presented that high rhinovirus inhibitory levels of the parent compound, A36683, can be maintained in mice (5) . A single oral dose of 300 mg/kg led to detectable levels of compound in the serum, urine, liver, and intestines up to 6 h after medication. A single oral dose of as little as 10 mg/kg allowed detectable levels of A36683 to remain in the serum for at least an hour. These results and our tissue culture observations warranted the present studies on the antiviral effect of the bis-benzimidazoles in murine LCM virus infections.
Mice continually receiving A36683 in the drinking water at a daily rate of 330 mg/kg did, indeed, have a high short-term survival rate after infection with large doses of two neurotropic strains of LCM virus. However, over 70% of these 30-day postinfection survivors died with LCM-like symptoms over the next 4 months. Sublethal amounts of X irradiation and a number of chemical compounds have been shown to prolong life, or spare mice, after normally lethal doses of LCM virus, with no apparent effect on virus synthesis. All of these responses have been explained on the basis of suppression of the immune response (3), which normally is the cause of death in adult mice infected with LCM virus. Regardless of the mode of action of the protective effect of A36683, its hydrochloride salt (A37536) was markedly less active. Possibly, the lower intake levels or chemical rearrangement in the low-pH drinking water could account for this. Four other bis-benzimidazole analogues (6) had no protective effect on LCM virus infections when used at 1 mg/ml in the drinking water (the protocols were the same as used in Fig. 1 ). Over half of the long-term A36683-treated survivors had virus titers in their blood comparable to those seen in neonatally infected adult carrier mice. A possible explanation is that bis-benzimidazole mutants have been selected for, as seen in vitro with HBB (1). This seems unlikely since A36683 has no apparent effect on virus replication in the mouse. A more likely explanation is that A36683 can induce a classic carrier state (3), as allowed in adult mice by use of certain immunosuppressants (2) .
